NASDAQ NMS - GLOBAL MARKET · LPCN
-1.44% · -$0.0300 · Vol 26.7K
Market closed · last close 4:00 PM ET · price as of 16:00:00 ET
Lipocine Inc

Lipocine Inc

Pharmaceuticals
$2.06
Card
Relationship Map

Veridion Score

BETAMEDIUM CONF · 5/6 factorsMethodology
Sentiment absence reason unknown
LPCN
Lipocine Inc
Mon Aug 24 · market closed · Markets closed · resumes Tue 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

60/ 100
Veridion Score
BUY BIAS · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5/6 factors with data · Mon Aug 24 · market closed · Markets closed · resumes Tue 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is LPCN moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading LPCN catalysts
About Lipocine Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2012
Employees
14
Country
US

Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.07
Day high
$2.10
Day low
$2.05
Previous close
$2.09
52W high
$11.26
-81.71% from high
52W low
$1.94
1% of range
Market cap
$17.2M
EPS
$-1.8600
Beta
1.29
Shares out
8.2M
Volume
26.7K
0.73× rel vol
Avg volume
36.7K
VWAP
$2.08
Price history computed in-house
1W
+0.98%
1M
-0.96%
3M
-9.65%
1Y
-31.79%
YTD
-74.35%
SMA 50 $2.24 · below
SMA 200 $4.53 · below
52W position 1%

LPCN overview

Veridion Score
60
Registered · 2026-08-24
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around LPCN.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading LPCN Form 4 filings
Public disclosures

Congress activity in LPCN

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for LPCN in the cached public ledger.

Federal contracts

LPCN contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for LPCN in this window.
Lobbying spend

LPCN lobbying filings, year to date.

Registered lobbying filings matched to Lipocine Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for LPCN in this window.
Loading news for LPCN
Analyst ratings
Sovereign unlock shows live analyst consensus for LPCN.
Options
Sovereign unlock shows live options positioning for LPCN.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.